Expression of a soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) correlates with clinical disease activity in intestinal Behcet's disease

Inflammatory Bowel Diseases

Volumn 17, Issue 10, 2011, Pages 2130-2137

  Jung, Yoon Suk ^a   Kim, Seung Won ^a   Yoon, Jin Young ^a   Lee, Jin Ha ^a   Jeon, Soung Min ^a   Hong, Sung Pil ^a   Kim, Tae Il ^a   Kim, Won Ho ^a   Cheon, Jae Hee ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

C reactive protein; disease activity index; erythrocyte sedimentation rate; intestinal Behcet's disease; triggering receptor expressed on myeloid cells 1; tumor necrosis factor

Indexed keywords

C REACTIVE PROTEIN; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BEHCET DISEASE; BLOOD ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE MARKER; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; INTESTINE BEHCET DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; BEHCET SYNDROME; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTESTINAL DISEASES; MALE; MEMBRANE GLYCOPROTEINS; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, IMMUNOLOGIC; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79955642270     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21600     Document Type: Article

References (44)

1. O'Duffy JD,. Behçet's disease. Curr Opin Rheumatol. 1994; 6: 39-43.
2. Kobayashi K, Ueno F, Bito S, et al. Development of consensus statements for the diagnosis and management of intestinal Behçet's disease using a modified Delphi approach. J Gastroenterol. 2007; 42: 737-745.
3. Bayraktar Y, Ozaslan E, Van Thiel DH,. Gastrointestinal manifestations of Behcet's disease. J Clin Gastroenterol. 2000; 30: 144-154.
4. Desai D, Faubion WA, Sandborn WJ,. Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther. 2007; 25: 247-255.
5. Colonna M,. TREMs in the immune system and beyond. Nat Rev Immunol. 2003; 3: 445-453.
6. Bouchon A, Dietrich J, Colonna M,. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol. 2000; 164: 4991-4995.
7. Tessarz AS, Cerwenka A,. The TREM-1/DAP12 pathway. Immunol Lett. 2008; 116: 111-116.
8. Gibot S, Cravoisy A, Dupays R, et al. Combined measurement of procalcitonin and soluble TREM-1 in the diagnosis of nosocomial sepsis. Scand J Infect Dis. 2007; 39: 604-608.
9. Gibot S, Cravoisy A, Kolopp-Sarda M, et al. Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C-reactive protein plasma concentrations during sepsis. Crit Care Med. 2005; 33: 792-796.
10. Radsak MP, Taube C, Haselmayer P, et al. Soluble triggering receptor expressed on myeloid cells 1 is released in patients with stable chronic obstructive pulmonary disease. Clin Dev Immunol. 2007; 2007: 52040.
11. Tejera A, Santolaria F, Diez M, et al. Prognosis of community acquired pneumonia (CAP): value of triggering receptor expressed on myeloid cells-1 (TREM-1) and other mediators of the inflammatory response. Cytokine. 2007; 38: 117-123.
12. Gibot S, Cravoisy A, Levy B, et al. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med. 2004; 350: 451-458.
13. Determann RM, Millo JL, Gibot S, et al. Serial changes in soluble triggering receptor expressed on myeloid cells in the lung during development of ventilator-associated pneumonia. Intensive Care Med. 2005; 31: 1495-1500.
14. Yasuda T, Takeyama Y, Ueda T, et al. Increased levels of soluble triggering receptor expressed on myeloid cells-1 in patients with acute pancreatitis. Crit Care Med. 2008; 36: 2048-2053.
15. Koussoulas V, Vassiliou S, Demonakou M, et al. Soluble triggering receptor expressed on myeloid cells (sTREM-1): a new mediator involved in the pathogenesis of peptic ulcer disease. Eur J Gastroenterol Hepatol. 2006; 18: 375-379.
16. Schenk M, Bouchon A, Seibold F, et al. TREM-1-expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases. J Clin Invest. 2007; 117: 3097-3106.
17. Park JJ, Cheon JH, Kim BY, et al. Correlation of serum-soluble triggering receptor expressed on myeloid cells-1 with clinical disease activity in inflammatory bowel disease. Dig Dis Sci. 2009; 54: 1525-1531.
18. Tzivras M, Koussoulas V, Giamarellos-Bourboulis EJ, et al. Role of soluble triggering receptor expressed on myeloid cells in inflammatory bowel disease. World J Gastroenterol. 2006; 12: 3416-3419.
19. Akoǧlu TF, Direskeneli H, Yazici H, et al. TNF, soluble IL-2R and soluble CD-8 in Behçet's disease. J Rheumatol. 1990; 17: 1107-1108.
20. Hamzaoui K, Hamza M, Ayed K,. Production of TNF-alpha and IL-1 in active Behçet's disease. J Rheumatol. 1990; 17: 1428-1429.
21. Mege JL, Dilsen N, Sanguedolce V, et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet's disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol. 1993; 20: 1544-1549.
22. Sayinalp N, Ozcebe OI, Ozdemir O, et al. Cytokines in Behçet's disease. J Rheumatol. 1996; 23: 321-322.
23. Evereklioglu C, Er H, Trkz Y, et al. Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease. Mediators Inflamm. 2002; 11: 87-93.
24. Bardak Y, Aridoǧan BC,. The demonstration of serum interleukin 6-8, tumor necrosis factor-alpha, complement, and immunoglobulin levels in Behçet's disease with ocular involvement. Ocul Immunol Inflamm. 2004; 12: 53-58.
25. Düzgün N, Ayaşlioǧlu E, Tutkak H, et al. Cytokine inhibitors: soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Behçet's disease. Rheumatol Int. 2005; 25: 1-5.
26. Oztas MO, Onder M, Gurer MA, et al. Serum interleukin 18 and tumour necrosis factor-alpha levels are increased in Behcet's disease. Clin Exp Dermatol. 2005; 30: 61-63.
27. Cheon JH, Kim ES, Shin SJ, et al. Development and validation of novel diagnostic criteria for intestinal Behçet's disease in Korean patients with ileocolonic ulcers. Am J Gastroenterol. 2009; 104: 2492-2499.
28. Cheon JH, Han DS, Park JY, et al. Development, validation, and responsiveness of a novel disease activity index for intestinal Behçet's disease. Inflamm Bowel Dis. 2010 [Epub ahead of print].
29. Coskun B, Saral Y, Gdekmerdan A, et al. Activation markers in Behçet's disease. Skinmed. 2005; 4: 282-286.
30. Müftüoǧlu AU, Yazici H, Yurdakul S, et al. Behçet's disease. Relation of serum C-reactive protein and erythrocyte sedimentation rates to disease activity. Int J Dermatol. 1986; 25: 235-239.
31. Aydintuǧ AO, Tokgz G, Ozoran K, et al. Elevated levels of soluble intercellular adhesion molecule-1 correlate with disease activity in Behçet's disease. Rheumatol Int. 1995; 15: 75-78.
32. Adam B, Calikoglu E,. Serum interleukin-6, procalcitonin and C-reactive protein levels in subjects with active Behçet's disease. J Eur Acad Dermatol Venereol. 2004; 18: 318-320.
33. Turan B, Gallati H, Erdi H, et al. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behcet's disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol. 1997; 24: 128-132.
34. Misumi M, Hagiwara E, Takeno M, et al. Cytokine production profile in patients with Behcet's disease treated with infliximab. Cytokine. 2003; 24: 210-218.
35. Kosar A, Haznedaroglu S, Karaaslan Y, et al. Effects of interferon-alpha2a treatment on serum levels of tumor necrosis factor-alpha, tumor necrosis factor-alpha2 receptor, interleukin-2, interleukin-2 receptor, and E-selectin in Behçet's disease. Rheumatol Int. 1999; 19: 11-14.
36. Akdeniz N, Esrefoglu M, Keleş MS, et al. Serum interleukin-2, interleukin-6, tumour necrosis factor-alpha and nitric oxide levels in patients with Behcet's disease. Ann Acad Med Singapore. 2004; 33: 596-599.
37. El Solh AA, Akinnusi ME, Peter M, et al. Triggering receptors expressed on myeloid cells in pulmonary aspiration syndromes. Intensive Care Med. 2008; 34: 1012-1019.
38. Ateş A, Kinikli G, Düzgün N, et al. Lack of association of tumor necrosis factor-alpha gene polymorphisms with disease susceptibility and severity in Behçet's disease. Rheumatol Int. 2006; 26: 348-353.
39. Curnow SJ, Pryce K, Modi N, et al. Serum cytokine profiles in Behçet's disease: is there a role for IL-15 in pathogenesis? Immunol Lett. 2008; 121: 7-12.
40. Zouboulis CC, Katsantonis J, Ketteler R, et al. Adamantiades- Behçet's disease: interleukin-8 is increased in serum of patients with active oral and neurological manifestations and is secreted by small vessel endothelial cells. Arch Dermatol Res. 2000; 292: 279-284.
41. Ebert EC,. Gastrointestinal manifestations of Behçet's disease. Dig Dis Sci. 2009; 54: 201-207.
42. Aouba A,. [Behçet's disease.] Rev Prat. 2008; 58: 533-540.
43. Yesudian PD, Edirisinghe DN, O'Mahony C,. Behçet's disease. Int J STD AIDS. 2007; 18: 221-227.
44. Ozdamar Y, Berker N, Bahar G, et al. Inflammatory mediators and posterior segment involvement in ocular Behcet disease. Eur J Ophthalmol. 2009; 19: 998-1003.